Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2140023 versus aripiprazole in schizophrenia with open-label LY2140023 extension
2010-023550-36Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pomaglumetad methionil and aripiprazole in schizophrenia (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in body weight during the double-blind treatment phase. Started Mar 2011; status: terminated.
02
Drugs
pomaglumetad methionilaripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-023550-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023550-36.